Hyperhomocysteine like risk factor in patient with systemic lupus erythematous with antiphospholipid sindrom

Objectives: to detect the prevalence of hyperhcy lo SLE patients with and without antiphospholipid syndrom; to compare the Hcy levels between those patients and healthy  controis and to determine the correlation between hyperhcy and antiphospholipid  antibodies. Patients and method...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Onetti, Laura, Villafañe, Susana, Menso, Emilia, Drenkard, Cristina, Gamron, Susana, Barberis, Gloria, Onetti, Carlos M
Formato: Artículo revista
Lenguaje:Español
Publicado: Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021
Materias:
.
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/27654
Aporte de:
Revista de la Facultad de Ciencias Médicas de Córdoba de Universidad Nacional de Córdoba
id I10-R327-article-27654
record_format ojs
institution Universidad Nacional de Córdoba
institution_str I-10
repository_str R-327
container_title_str Revista de la Facultad de Ciencias Médicas de Córdoba
language Español
format Artículo revista
topic .
spellingShingle .
Onetti, Laura
Villafañe, Susana
Menso, Emilia
Drenkard, Cristina
Gamron, Susana
Barberis, Gloria
Onetti, Carlos M
Hyperhomocysteine like risk factor in patient with systemic lupus erythematous with antiphospholipid sindrom
topic_facet .
author Onetti, Laura
Villafañe, Susana
Menso, Emilia
Drenkard, Cristina
Gamron, Susana
Barberis, Gloria
Onetti, Carlos M
author_facet Onetti, Laura
Villafañe, Susana
Menso, Emilia
Drenkard, Cristina
Gamron, Susana
Barberis, Gloria
Onetti, Carlos M
author_sort Onetti, Laura
title Hyperhomocysteine like risk factor in patient with systemic lupus erythematous with antiphospholipid sindrom
title_short Hyperhomocysteine like risk factor in patient with systemic lupus erythematous with antiphospholipid sindrom
title_full Hyperhomocysteine like risk factor in patient with systemic lupus erythematous with antiphospholipid sindrom
title_fullStr Hyperhomocysteine like risk factor in patient with systemic lupus erythematous with antiphospholipid sindrom
title_full_unstemmed Hyperhomocysteine like risk factor in patient with systemic lupus erythematous with antiphospholipid sindrom
title_sort hyperhomocysteine like risk factor in patient with systemic lupus erythematous with antiphospholipid sindrom
description Objectives: to detect the prevalence of hyperhcy lo SLE patients with and without antiphospholipid syndrom; to compare the Hcy levels between those patients and healthy  controis and to determine the correlation between hyperhcy and antiphospholipid  antibodies. Patients and methods: we studied 44 SLE patients: 17 had antiphospholipid syndrom and  27 didn't have it, and we compared them to 24 hcalthy controls. All of them where checked  clinically and with laboratory tests like anticardiolypin antibodies, lupus anticoagulant and  Hcy. Hcy> 9 was considered abnormal. Patient who had hyperhcy were treated with folie acid+vitB6+vitBl2 a nionth along.  Statistical analysis: cualytative variables: chi square or  Fischer's; cuantitative variables: Student's T test or Mann- Whitney's test. Results and conclutions: there were 35 tromhotic manifestations in 44 patients. Hyperhcy  was present in 27 SLE patients (61,4%), 12 of them had antiphospholipid syndrom. Hcy  concentrations patients vs.controls was statisticaly different (p=0,002). There was also  stastisticaly different the bey concentration from SLE patients with SAF vs controis  (p=0,003) and without SAF vs controis (p= 0.0 15). From 33 SLE patients, 20 (33%) were aCL(+). 15(75%) of them had hiperhcy
publisher Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
publishDate 2021
url https://revistas.unc.edu.ar/index.php/med/article/view/27654
work_keys_str_mv AT onettilaura hyperhomocysteinelikeriskfactorinpatientwithsystemiclupuserythematouswithantiphospholipidsindrom
AT villafanesusana hyperhomocysteinelikeriskfactorinpatientwithsystemiclupuserythematouswithantiphospholipidsindrom
AT mensoemilia hyperhomocysteinelikeriskfactorinpatientwithsystemiclupuserythematouswithantiphospholipidsindrom
AT drenkardcristina hyperhomocysteinelikeriskfactorinpatientwithsystemiclupuserythematouswithantiphospholipidsindrom
AT gamronsusana hyperhomocysteinelikeriskfactorinpatientwithsystemiclupuserythematouswithantiphospholipidsindrom
AT barberisgloria hyperhomocysteinelikeriskfactorinpatientwithsystemiclupuserythematouswithantiphospholipidsindrom
AT onetticarlosm hyperhomocysteinelikeriskfactorinpatientwithsystemiclupuserythematouswithantiphospholipidsindrom
AT onettilaura hiperhomocisteinemiacomofactorderiesgotroboticoenpacientesconlupuseritematositemicoysindromeantifosfolipido
AT villafanesusana hiperhomocisteinemiacomofactorderiesgotroboticoenpacientesconlupuseritematositemicoysindromeantifosfolipido
AT mensoemilia hiperhomocisteinemiacomofactorderiesgotroboticoenpacientesconlupuseritematositemicoysindromeantifosfolipido
AT drenkardcristina hiperhomocisteinemiacomofactorderiesgotroboticoenpacientesconlupuseritematositemicoysindromeantifosfolipido
AT gamronsusana hiperhomocisteinemiacomofactorderiesgotroboticoenpacientesconlupuseritematositemicoysindromeantifosfolipido
AT barberisgloria hiperhomocisteinemiacomofactorderiesgotroboticoenpacientesconlupuseritematositemicoysindromeantifosfolipido
AT onetticarlosm hiperhomocisteinemiacomofactorderiesgotroboticoenpacientesconlupuseritematositemicoysindromeantifosfolipido
first_indexed 2024-09-03T21:01:41Z
last_indexed 2024-09-03T21:01:41Z
_version_ 1809210200519868416
spelling I10-R327-article-276542024-08-27T18:27:36Z Hyperhomocysteine like risk factor in patient with systemic lupus erythematous with antiphospholipid sindrom Hiperhomocisteinemia como factor de riesgo trobótico en pacientes con lupus eritemato sitémico y síndrome antifosfolípido Onetti, Laura Villafañe, Susana Menso, Emilia Drenkard, Cristina Gamron, Susana Barberis, Gloria Onetti, Carlos M . Objectives: to detect the prevalence of hyperhcy lo SLE patients with and without antiphospholipid syndrom; to compare the Hcy levels between those patients and healthy  controis and to determine the correlation between hyperhcy and antiphospholipid  antibodies. Patients and methods: we studied 44 SLE patients: 17 had antiphospholipid syndrom and  27 didn't have it, and we compared them to 24 hcalthy controls. All of them where checked  clinically and with laboratory tests like anticardiolypin antibodies, lupus anticoagulant and  Hcy. Hcy> 9 was considered abnormal. Patient who had hyperhcy were treated with folie acid+vitB6+vitBl2 a nionth along.  Statistical analysis: cualytative variables: chi square or  Fischer's; cuantitative variables: Student's T test or Mann- Whitney's test. Results and conclutions: there were 35 tromhotic manifestations in 44 patients. Hyperhcy  was present in 27 SLE patients (61,4%), 12 of them had antiphospholipid syndrom. Hcy  concentrations patients vs.controls was statisticaly different (p=0,002). There was also  stastisticaly different the bey concentration from SLE patients with SAF vs controis  (p=0,003) and without SAF vs controis (p= 0.0 15). From 33 SLE patients, 20 (33%) were aCL(+). 15(75%) of them had hiperhcy Objetivos: Determinar la prevalencia de hiperhomocisteinemia (hiperhcy) en pacientes con  lupus eritematoso sistémico (LES) con y sin síndrome antifosfolípido (SAF); comparar los  niveles de homocisteína (Hcy) entre pacientes con LES (con y sin SAF asociado) y un  grupo de controles sanos y determinar la correlación entre hiperhcy y la presencia de  anticuerpos antifosfolípiclos. Pacientes y métodos: Se estudiaron 44 ptes con LES, portadores o no de SAF. Se los  dividió en 2 grupos: 17 con LES y SAF y 27 con LES sin SAF y se compararon con 24  controles sanos. A todos se les realizó interrogatorio, examen físico y pruebas de  laboratorio: anticuerpos anticardiolipinas (aCL), anticoagulante lúpico y Hcy. Se consideró hiperhcv a valores superiores a 9. A los ptes con hiperhcy se los trató con ácido fálico + B6    B12 durante un mes. Análisis estadístico: variables cualitativas: Chi cuadrado o Exacta de  Fischer y cuantitativas: test T de Student o Mann- Whitney test. Resultados y conclusiones: Hubo 35 manifestaciones trombóticas en los 44 pacientes. Se  encontró Hiperhcy en 27 pies con LES (61,4%), de los cuales 12 tenían SAE La diferencia  entre los valores de Hcy de los pacientes con o sin SAE no fue significativa (p=0,42).  Comparando las concentraciones de Hcy entre pacientes y controles, la diferencia fue muy significativa (p=0.002).Tainbién tuvo significación estadística la diferencia entre las  concentraciones de Hcy de los pacientes con LES sin SAF vs. controles (p=0.015) y LES  con SAE vs. controles (p=O.003). A 33 ptes se les dosó aCL: 20 (60.6%) fueron (+). De  estos, 15 (75%) tenían hiperhcy. De los 27 pacientes con LES que tenían hiperhcy. sólo 18  cumplieron con el mes de tratamiento con a.fólico+136+B12. 16 de 18 (88,8%)  normalizaron o disminuyeron la Hcy. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021-03-25 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf https://revistas.unc.edu.ar/index.php/med/article/view/27654 10.31053/1853.0605.v62.n1.27654 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 62 No. 1 (2005); 21- 25 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 62 Núm. 1 (2005); 21- 25 Revista da Faculdade de Ciências Médicas de Córdoba; v. 62 n. 1 (2005); 21- 25 1853-0605 0014-6722 spa https://revistas.unc.edu.ar/index.php/med/article/view/27654/29095 Derechos de autor 2021 Universidad Nacional de Córdoba https://creativecommons.org/licenses/by-nc/4.0

Ejemplares similares